৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬



Quantity:
Products
Payment
Delivery
Upacit XR is a Janus Kinase (JAK) inhibitor indicated for the treatment of:
Upadacitinib is a selective Janus Kinase (JAK) inhibitor. It works by inhibiting JAK enzymes involved in cytokine signaling pathways, thereby reducing inflammation and modulating immune responses. This inhibition prevents the phosphorylation and activation of STAT proteins that regulate gene expression and immune cell function.
Rheumatoid Arthritis
Psoriatic Arthritis
Atopic Dermatitis
Ulcerative Colitis
Crohn's Disease
Ankylosing Spondylitis
Non-radiographic Axial Spondyloarthritis
Polyarticular Juvenile Idiopathic Arthritis
Strong CYP3A4 Inhibitors (e.g., Ketoconazole)
Strong CYP3A4 Inducers (e.g., Rifampin)
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Atopic Dermatitis
Ulcerative Colitis
Crohn's Disease



Rheumatoid Arthritis
Rheumatoid Arthritis\r\nIndicated for moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate\r\n\r\n15 mg PO qDay\r\n\r\nMay be used as monotherapy or in combination with methotrexate or other nonbiological DMARDs\r\n\r\nHepatic impairment\r\nMild or moderate (Child-Pugh A or B): No dose adjustment required\r\nSevere (Child-Pugh C): Not recommended
Renal impairment\r\nMild, moderate, or severe: No dose adjustment required\r\nESRD: Not studied\r\n
Janus kinase-1 (JAK1)-selective inhibitor; JAK1 is essential for signaling for certain cytokines to elicit signals from various interleukins, cardiotrophin, neurotrophin, and interferons\r\n\r\nThese signals are essential in maintaining the inflammatory condition in rheumatoid arthritis (RA); inhibition of JAK reduces production of and modulates proinflammatory cytokines central to RA
Malignancies reported; consider risks and benefits of treatment before initiating in patients with known malignancy, other than previously treated nonmelanoma skin cancer; screen for malignancies during treatment according to guidelines\r\n\r\nThrombosis reported, including DVT, PE, and arterial thrombosis\r\n\r\nGastrointestinal perforation reported; unknown if JAK inhibition is implicated in these events; many patients were also receiving NSAIDs\r\n\r\nMay cause neutropenia, lymphopenia, anemia, elevated lipids, or elevated liver enzymes; monitor for abnormal laboratory values and assess the need to interrupt dosing\r\n\r\nBased on findings in animal studies, may cause fetal harm when administered to pregnant women
>10%\r\nUpper respiratory tract infection (13.5%)\r\n\r\n1-10%\r\nNausea (3.5%)\r\n\r\nNeutropenia (1.1-2.4%)\r\n\r\nLymphopenia (0.3-2.4%)\r\n\r\nCough (2.2%)\r\n\r\nElevated ALT (0.8-2.1%)\r\n\r\nIncreased creatine phosphokinase (0.3-1.6%)\r\n\r\nElevated AST (1-1.5%)\r\n\r\nPyrexia (1.2%)\r\n\r\n<1%\r\nPneumonia\r\n\r\nHerpes zoster\r\n\r\nHerpes simplex (includes oral herpes)\r\n\r\nOral candidiasis\r\n\r\nAnemia (<0.1%)
$4e
N/A


